PLGA Nanoparticles synthesis service

- Drug or any gene regulators, including siRNA, plasmid DNA, AAV vector or CRISPR can be loaded in PLGA nanoparticlesEncapsulation efficiency of PLGA NPs is about 30% which is proved by drug releasing assay.


Amidst the various polymers synthesized for formulating polymeric nanoparticles, poly(lactic-co-glycolic acid) (PLGA) is the most popular. PLGA has several interesting properties such as controlled and sustained release, low cytotoxicity, long-standing biomedical applications, biocompatibility with tissues and cells, prolonged residence time and targeted delivery.
PLGA has already been approved by the US FDA as a therapeutic device owing to its biodegradability and biocompatibility. PLGA NPs are one of the potential device to deliver a various regulators, including siRNA, plasmid DNA, AAV vectors or CRISPR, which regulate the gene expression.

Product Specifications
- Formula :
-  Storage/Stability :
  1. -20 ℃ with powder for long time
  2. Solubility :Soluble in autoclaved water or  PBS stable at +4℃ for 1-2 weeks.

Figure 1. Characterization of small-interfering RNA-encapsulated PLGA nanoparticles. siRNA-encapsulated PLGA nanoparticles were dissolved in water and measured for size and Zeta potential using a Zetasizer. And suspended nanoparticles were also assessed by TEM.

Figure 2. PLGA nanoparticles localize in hippocampus and cortex of normal mouse brain. Three days after intrathecal injection of AAV-mCherry NPs (40 μg / 20 μl), examined under a fluorescent microscope to assess cellular uptake.

Popular posts from this blog

Congratulations to all contributors